Puma Biotech (PBYI) – Business Wire
-
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
-
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference
-
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
-
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
-
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference
-
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Puma Biotechnology Reports Third Quarter 2023 Financial Results
-
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results
-
Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecula
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer
-
Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
-
Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
-
Puma Biotechnology Reports Second Quarter Financial Results
-
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Puma Biotechnology Reports First Quarter Financial Results
-
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology
-
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
-
Puma Biotechnology to Participate in a Panel Discussion at Cowen’s 43rd Annual Health Care Conference
-
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation
-
Puma Biotechnology to Present at B. Riley Securities’ 3rd Annual Oncology Conference
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Puma Biotechnology Releases Updated Corporate Presentation
-
Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Puma Biotechnology Reports Third Quarter 2022 Financial Results
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
-
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor
-
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022
-
Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Toragen, Inc. Announces the Appointment of Board of Directors and Senior Staff
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Back to PBYI Stock Lookup
